Search Results - Meghan Feely

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA by Andrew Blauvelt, Alyssa Garrelts, William Malatestinic, Julie Birt, Baojin Zhu, Meghan Feely

Connect to this object online.

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry by Jonathan I. Silverberg, Evangeline Pierce, Meghan Feely, Amber Reck Atwater, Amy Schrader, Eric A. Jones, Swapna S. Dave, Eric L. Simpson

Connect to this object online.

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab... by Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H. Chih-Ho Hong, Meghan Feely, Alyssa Garrelts, Kyoungah See, Bruce Konicek, Lawrence Green

Connect to this object online.

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2 by Susan Taylor, Neil J. Korman, Tsen-Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen-Shuo Wu, Najwa Somani, Antonella Tosti

Connect to this object online.

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt

Connect to this object online.

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-Wo... by April Armstrong, Alvaro González-Cantero, Saakshi Khattri, Guilherme Muzy, William N. Malatestinic, Anastasia Lampropoulou, Meghan Feely, Sophia Kyoungah See, Can Mert, Andrew Blauvelt

Connect to this object online.

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)... by Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong

Connect to this object online.